SVT-RS107

SVT-RS107 is an investigational topical ophthalmic formulation being developed by Laboratorios Salvat for the treatment of diabetic retinopathy. The drug utilizes Salvat's proprietary IMPACT-SVT® nanoemulsion technology, which is specifically engineered to enhance the penetration of active ingredients through ocular tissues to reach the retina via topical administration. This delivery platform aims to provide a non-invasive alternative to traditional intravitreal injections for posterior segment diseases. While the specific active pharmaceutical ingredient and its biological target remain undisclosed, the candidate is a key part of Salvat's strategy to apply advanced drug delivery systems to established therapeutic classes in ophthalmology.